


Quality of life with palbociclib plus fulvestrant *versus* placebo plus fulvestrant in postmenopausal women with endocrine-sensitive hormone receptor-positive and HER2-negative advanced breast cancer: patient-reported outcomes from the FLIPPER trial

Ariadna Tibau , M. Teresa Martínez, Manuel Ramos, Luis De La Cruz-Merino, Ana Santaballa, Miriam O'Connor, Noelia Martínez-Jañez, Fernando Moreno, Isaura Fernández, Juan Antonio Virizuela, Jesús Alarcón, Juan de La Haba-Rodríguez, Pedro Sánchez-Rovira, Cinta Rosa Albacar, Coralía Bueno Muño, Catherine Kelly, Maribel Casas, Susana Bezares, Libertad Rosell and Joan Albanell

Abstract

Background: In the FLIPPER trial, palbociclib/fulvestrant significantly improved progression-free survival (PFS) compared with placebo/fulvestrant in postmenopausal women with HR+/HER2- advanced breast cancer (ABC).

Objective: We assessed health-related quality of life (QoL) using patient-reported outcomes (PROs).

Design and methods: In this phase II double-blinded study, PROs were assessed at baseline after every three cycles and at the end of the treatment using the European Organisation for Research and Treatment of Cancer QLQ-C30 and QLQ-BR23. Time to deterioration (TTD) in global health status (GHS)/QoL was defined as a decrease of ≥ 10 points. Changes from baseline (CFB) and TTD were analysed using linear mixed-effect and Cox regression models, respectively.

Results: Of the 189 randomised (1:1) patients, 178 (94%) completed ≥ 1 post-baseline assessment; 50% received ≥ 22 cycles of study treatment, with a questionnaire compliance $> 90\%$. Mean baseline scores were comparable between arms. GHS/QoL scores were maintained throughout the palbociclib/fulvestrant treatment. CFB showed significant differences for GHS/QoL, appetite loss, constipation and systemic therapy side effect scores favouring placebo/fulvestrant. TTD in GHS/QoL was delayed in placebo/fulvestrant *versus* palbociclib/fulvestrant [30.3 *versus* 11.1 months; adjusted hazard ratio (aHR): 1.57, 95% CI: 1.03–2.39, $p=0.036$]; this difference was not significant in patients with progressive disease (aHR: 1.2, 95% CI: 0.6–2.2, $p=0.658$). No statistically significant differences in TTD were found for the other QLQ-C30 and QLQ-BR23 scales.

Conclusions: Although TTD in GHS/QoL was prolonged with placebo/fulvestrant, no differences were observed on other functional or symptom scales. This finding and the improvement in PFS support the combination of palbociclib/fulvestrant as a beneficial therapeutic option for HR+/HER2- ABC.

Trial registration number: Sponsor Study Code: GEICAM/2014-12
EudraCT Number: 2015-002437-21
ClinTrials.gov reference: NCT02690480

Ther Adv Med Oncol

2023, Vol. 15: 1–14

DOI: 10.1177/
17588359221148921

© The Author(s), 2023.
Article reuse guidelines:
sagepub.com/journals-
permissions

Correspondence to:

Ariadna Tibau
Hospital de la Santa
Creu i Sant Pau,
Institut d'Investigació
Biomèdica Sant Pau, and
Departament de Medicina
de la Universitat Autònoma
de Barcelona, C/ Sant
Quintí, 89, Barcelona
08041, Spain

GEICAM Spanish Breast
Cancer Group, Madrid,
Spain.

atibau@santpau.cat

M. Teresa Martínez
GEICAM Spanish Breast
Cancer Group, Madrid,
Spain

Hospital Clínico
Universitario de Valencia,
Instituto de Investigación
Sanitaria-INCLIVA,
Valencia, Spain

Manuel Ramos
GEICAM Spanish Breast
Cancer Group, Madrid,
Spain

Centro Oncológico de
Galicia, Coruña, Spain

Luis De La Cruz-Merino
GEICAM Spanish Breast
Cancer Group, Madrid,
Spain

Hospital Universitario
Virgen de la Macarena,
Medicine Department-
Universidad de Sevilla,
Sevilla, Spain

Ana Santaballa
GEICAM Spanish Breast
Cancer Group, Madrid,
Spain

Hospital Universitario
y Politécnico La Fe,
Valencia, Spain

Miriam O'Connor
University Hospital
Waterford, Waterford,
Ireland

Cancer Trials Ireland,
Dublin, Ireland

Noelia Martínez-Jañez
GEICAM Spanish Breast
Cancer Group, Madrid,
Spain

Hospital Universitario
Ramón y Cajal, Madrid,
Spain

Fernando Moreno

GEICAM Spanish Breast Cancer Group, Madrid, Spain

Hospital Clínico Universitario San Carlos, Madrid, Spain

Isaura Fernández

GEICAM Spanish Breast Cancer Group, Madrid, Spain

Hospital Álvaro Cunqueiro, Vigo, Spain

Juan Antonio Virizuela

GEICAM Spanish Breast Cancer Group, Madrid, Spain

Hospital QuirónSalud Sagrado Corazón, Sevilla, Spain

Jesús Alarcón

GEICAM Spanish Breast Cancer Group, Madrid, Spain

Hospital Universitari Son Espases, Palma de Mallorca, Spain

Juan de La Haba-Rodríguez

GEICAM Spanish Breast Cancer Group, Madrid, Spain

Instituto Maimonides de Investigación Biomedica, Hospital Reina Sofía Hospital, Universidad de Córdoba, Spain

Centro de Investigación Biomédica en Red de Oncología, CIBERONC-ISCIII, Madrid, Spain

Pedro Sánchez-Rovira

GEICAM Spanish Breast Cancer Group, Madrid, Spain

Hospital Universitario de Jaén, Jaén, Spain

Cinta Rosa Albacar

GEICAM Spanish Breast Cancer Group, Madrid, Spain

Hospital Universitario Sant Joan de Reus, Spain

Coralia Bueno Muño

GEICAM Spanish Breast Cancer Group, Madrid, Spain

Hospital Infanta Cristina (Parla), Fundación de Investigación Biomédica del H.U. Puerta de Hierro Majadahonda, Madrid, Spain

Catherine Kelly

Cancer Trials Ireland, Dublin, Ireland Mater

Misericordiae University Hospital, Ireland

Maribel Casas

Susana Bezares

Libertad Rosell

GEICAM Spanish Breast Cancer Group, Madrid, Spain

Keywords: advanced breast cancer, CDK4/6 inhibitor, fulvestrant, palbociclib, patient-reported outcomes, quality of life

Received: 9 June 2022; revised manuscript accepted: 15 December 2022.

Introduction

In the FLIPPER trial (ClinTrials.gov number, NCT02690480), the efficacy and safety of the CDK4/6 inhibitor palbociclib plus fulvestrant was compared with placebo plus fulvestrant for the treatment of postmenopausal woman with endocrine-sensitive hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC). Primary results demonstrated a statistically significant improvement for a number of metrics with palbociclib/fulvestrant as compared to placebo/fulvestrant. Specifically, 1-year progression-free survival (PFS) rate [83.5% *versus* 71.9%; hazard ratio (HR): 0.55, 80% confidence interval (CI): 0.36–0.83, $p=0.064$], PFS [median 31.8 *versus* 22.0 months; adjusted HR (aHR): 0.48; 80% CI: 0.37–0.64, $p=0.001$] and overall response rate (68.3% *versus* 42.2%; odds ratio: 2.9; 80% CI: 1.8–4.6, $p=0.004$) with a manageable safety profile. Results on overall survival (OS) are still immature¹

The addition of CDK4/6 inhibitors to endocrine therapy (ET) as first-line therapy for postmenopausal woman with HR+/HER2- ABC leads to a statistically and clinically significant improvement in PFS when compared with endocrine monotherapy.^{2–4} However, combination treatments can expose patients to additional treatment-related toxicities, which may negatively affect their quality of life (QoL). Recommendations from medical oncology societies experts and regulators highlight the need for integration of patient-reported outcomes (PROs) into the discussion of efficacy and safety drug profile to better define their clinical benefit.^{5–7} Here, we report validated cancer-related and breast cancer-specific PRO results from the FLIPPER trial.

Material and methods

Study design and patients

The FLIPPER is a phase II, randomised, international, multicentre, double-blinded, placebo-controlled trial comparing the efficacy of palbociclib/

fulvestrant *versus* placebo/fulvestrant in postmenopausal women with HR+/HER2- ABC. Patients had either *de novo* metastatic disease or remained disease free for >12 months after completing at least 5 years of adjuvant ET. Patients were assigned in a 1:1 ratio to receive palbociclib (125 mg/day, 28-day cycle; 3 weeks on, 1 week off) or matched placebo, and both arms received fulvestrant (500 mg on day 1 of each 28-day cycle, with an additional dose on day 15 of cycle 1). Treatment continued until objective progressive disease (PD) according to the Response Evaluation Criteria in Solid Tumours version 1.1,⁸ symptomatic deterioration, unacceptable toxicity, death or withdrawal of consent, according to which occurred first. The detailed study design and characteristics of patients have been reported previously.¹

PRO assessments

The comparison of the health-related QoL (HRQoL) between treatment arms as reported by patients was a secondary objective of the trial using as secondary endpoints the changes from baseline (CFB) and time to deterioration (TTD) PRO measures of HRQoL were assessed using the European Organisation for Research and Treatment of Cancer (EORTC) QoL questionnaire-Core 30 (QLQ-C30) V3.0⁹ and its breast cancer-specific module (QLQ-BR23; v1.0).¹⁰

Patients were asked to complete each questionnaire at baseline, every three cycles until the end of treatment, and at the post-treatment visit (performed 30 days after the last study treatment dose). Questionnaires were completed by patients in the clinic environment prior to any testing or discussion with healthcare personnel at the site.

The EORTC QLQ-C30 is a 30-item questionnaire composed of a global health status (GHS)/QoL multi-item scale, five multi-item functional scales (physical, role, emotional, cognitive and social), three multi-item symptom scales (fatigue, nausea/vomiting and pain) and six single-item symptom scales (dyspnoea, insomnia, appetite

loss, constipation, diarrhoea and financial difficulties)⁹ (Table 1). The EORTC QLQ-BR23 questionnaire is a 23-item companion module consisting of two multi-item functional scales (body image and sexual functioning) and three multi-item symptom scales (systemic therapy side effects, arm and breast symptoms) and single item functional and symptom scales covering sexual enjoyment, future perspective and upset due to hair loss¹⁰ (Table 1).

Two seven-point Likert scales for GHS/QoL with responses from 'very poor' to 'excellent' and four-point Likert scales to assess functioning and symptoms with responses from 'not at all' to 'very much' were provided.

Responses to all item measures were converted into linear scales ranging from 0 to 100 using a standard scoring algorithm.¹¹ For the GHS/QoL and functional scales, a higher score represents a better level of QoL/functioning and an increase from baseline indicates an improvement in QoL. By contrast, for symptomatic scales, a higher numerical score represents greater or worse symptom severity.

Statistical analysis

PROs analyses were performed in cases with baseline and at least one post-baseline assessment (QoL population). Completion rates were summarised by visit in the intention-to-treat (ITT) population; a questionnaire was considered received if at least one question was answered. For partially completed multi-item scales, missing scores were equal to the average of the completed items if at least half of the items of that scale were answered, but were not included in the analysis if less than that were completed.

Descriptive statistics, including 95% CI for the means of actual values and CFB were tabulated at the scheduled time points for each scale of the EORTC QLQ-C30 and EORTC QLQ-BR23 questionnaires. The means and 95% CIs of CFB, as well as comparisons between treatment arms with their respective p-values, were analysed using a linear mixed model. The model factors were treatment arms, time points, treatment–time interaction terms, and stratification criteria, and the covariates were the baseline scores. A random-intercept only model with a first-order autoregressive covariance structure was used.

Table 1. Item numbers and definition of the MID as CFB values by scale in the EORTC QLQ-C30 and QLQ-BR23 instruments.

Instruments, scales	Item number ^b	MID ^a
EORTC QLQ-C30		
Functional scales		
Physical functioning	1–5	6
Role functioning	6–7	8
Emotional functioning	21–24	4
Cognitive functioning	20, 25	2
Social functioning	26, 27	7
QoL		
GHS/QoL	29, 30	10
Symptom scales		
Fatigue	10, 12, 18	6
Nausea and vomiting	14, 15	6
Pain	9, 19	4
Dyspnoea	8	6
Insomnia	11	3
Appetite loss	13	3
Constipation	16	6
Diarrhoea	17	6
Financial difficulties	28	3
EORTC QLQ-BR-23		
Functional scales		
Body image	9–12	5
Sexual functioning	14, 15	5
Sexual enjoyment	16	5
Future perspective	13	5
Symptom scales		
Systemic therapy side effects	1–4, 6, 7, 8	5
Breast symptoms	20–23	5
Arm symptoms	17, 18, 19	5
Upset by hair loss	5	5

Source: Cocks *et al.*¹² and Osoba *et al.*¹³

^aA deterioration event is an increase of \geq MID from baseline for the symptom scales and a decrease of \geq MID from baseline for the functional scales and GHS/QoL. A clinically meaningful is a decrease of \geq MID from baseline for the symptom scales and an increase of \geq MID from baseline for the functional scales and GHS/QoL.

^bThe GHS/QoL items were rated on a seven-point Likert scales with responses from 'very poor' to 'excellent' and the other QLQ-C30 items and all QLQ-BR23 items were rated on a four-point Likert scale from 'not at all' to 'very much'.

CFB, change from baseline; EORTC QLQ-BR-23, European organisation for research and treatment of cancer breast-specific questionnaire; EORTC QLQ-C30, European organisation for research and treatment of cancer core questionnaire; GHS/QoL, global health status/QoL; MID, minimally important difference.

Joan Albanell

GEICAM Spanish Breast Cancer Group, Madrid, Spain

Centro de Investigación Biomédica en Red de Oncología, CIBERONC-ISCIII, Madrid, Spain

Hospital del Mar Medical Research Institute (IMIM), Hospital del Mar, Barcelona, Spain

Pompeu Fabra University, Barcelona, Spain

Baseline scores were compared between treatment arms using t-test.

TTD investigated both in the entire study QoL population and in subgroups, according to therapy response (with/without PFS event), was defined as the time from the date of randomisation to the date of first detection of a deterioration event. The minimally important difference (MID) is the change in score of a PRO that is important from the patient's or clinician's perspective and would warrant a change in the patient's management. The MID values used were between 2 and 10 points according to data previously published.^{12,13} A deterioration event was defined as an increase of \geq MID from baseline for the EORTC QLQ-C30 and QLQ-BR23 symptom scales and a decrease of \geq MID from baseline for the EORTC QLQ-C30 and QLQ-BR23 functional and GHS scales. Results were defined as clinically meaningful based on MID for EORTC QLQ-C30 and QLQ-BR23 (Table 1). Patients with no definitive deterioration event were censored at their last available QoL assessment. In patients with no post-baseline assessment, TTD was censored on day 1.

The Kaplan–Meier method was used to estimate the distribution of TTD for each treatment arm and according to PFS event. A log-rank test was performed to compare the TTD between treatment arms. HRs were adjusted by stratification factors: disease site (visceral *versus* non-visceral) and (recurrent *versus de novo* metastatic disease). Adjusted HR (aHRs) and two-sided 95% CIs were estimated using Cox regression model for the comparison of treatment arms.

Results

Patient characteristics

Between February 2016 and January 2018, 189 patients were recruited across 32 institutions in two countries [177 patients in Spain (GEICAM) and 12 in Ireland (Clinical Trials Ireland)]. The QoL population comprised 178 (94.2%) patients with completed baseline and \geq 1 post-baseline PROs. Of these, 88 were included in the palbociclib/fulvestrant arm and 90 in the placebo/fulvestrant arm (Supplemental Figure S1).

Baseline demographic and disease characteristics were well balanced between arms (Supplemental

Table S1). Median age was 64 years, 97% of patients had an Eastern Cooperative Oncology Group performance status of zero or one, 45.5% had *de novo* metastatic disease and among those having non-*de novo* metastatic disease, 39.7% had a treatment-free interval after adjuvant ET greater than 36 months. Most patients (60.3%) had visceral involvement; overall, 33.9% patients had lung involvement, 15.9% liver involvement and 15.9% bone-only disease.

Completion rates

All PRO analyses were based on a cut-off date of 11 January 2020, at a median follow-up time of 28.6 months (range, from 1.5 to 44.8). At this point, 50% of patients had received the first 22 cycles of study treatment and the overall questionnaire compliance was high in both treatment arms, with a completion rate \geq 96% at baseline, \geq 92% on treatment and \geq 84% at post-treatment visit (Supplemental Table S2).

The compliance rates of each EORTC QLQ-C30, EORTC QLQ-BR23 scale were like the global questionnaire completion rates, except for sexual enjoyment and, upset due to hair loss, where sample sizes were smaller *versus* other scales (Table 2).

EORTC QLQ-C30 and QLQ-BR23 baseline scores

Mean baseline scores were similar in all dimensions among the treatment arms, except for the body image, with better level of functioning in placebo/fulvestrant arm (Table 2). Globally, all baseline scores were in line with the EORTC QLQ-C30, QLQ-BR23 reference values expected for ABC.¹⁴

CFB per treatment arm

Palbociclib/fulvestrant. The combination of palbociclib/fulvestrant showed a GHS/QoL mean scores maintained numerically up to cycle 22, and a decrease occurred at the post-treatment visit (Figure 1). When analysing the mean CFB by visit, significant improvement at different time points was found for emotional functioning, social functioning, body image, pain, dyspnoea, diarrhoea, breast symptom and arm symptom (Supplemental Table S3). Meanwhile, significant impairment was found for future perspective, constipation, financial difficulties and systemic

Table 2. Baseline mean scores of EORTC QLQ-C30 and EORTC QLQ-BR23 scales by treatment arm.

	Palbociclib/fulvestrant <i>n</i> = 88		Placebo/fulvestrant <i>n</i> = 90		<i>p</i> Value t-test	Reference values ^a
	<i>n</i>	Mean (SD)	<i>n</i>	Mean (SD)		
EORTC QLQ-C30 functional scales						
Physical functioning	88	75.4 (21.3)	90	77.9 (23.1)	0.445	81.6 (18.7)
Role functioning	88	72.2 (29.4)	90	72.2 (33.2)	0.989	67.4 (31.1)
Emotional functioning	88	63.5 (25.8)	90	69.2 (23.5)	0.121	65.9 (24.6)
Cognitive functioning	88	87.5 (16.8)	90	88.3 (19.7)	0.762	80.5 (23.2)
Social functioning	87	79.1 (25.3)	88	85.2 (21.7)	0.088	74.2 (28.4)
EORTC QLQ-C30 QoL						
GHS/QoL	88	60.0 (24.2)	90	57.0 (25.6)	0.423	60.2 (25.5)
EORTC QLQ-C30 symptom scales						
Fatigue	88	34.0 (26.0)	90	29.3 (27.1)	0.238	36.3 (27.0)
Nausea and vomiting	88	2.8 (6.8)	90	5.4 (14.7)	0.143	10.3 (19.7)
Pain	88	35.6 (31.7)	90	30.6 (30.2)	0.278	30.9 (29.6)
Dyspnoea	88	22.7 (31.4)	90	15.6 (25.1)	0.094	20.4 (28.2)
Insomnia	88	26.9 (30.3)	89	33.3 (31.4)	0.167	33.1 (32.6)
Appetite loss	88	19.3 (26.6)	90	19.3 (29.1)	0.989	21.7 (31.0)
Constipation	88	20.1 (30.1)	90	17.8 (26.1)	0.587	19.2 (28.8)
Diarrhoea	88	6.8 (14.4)	90	5.2 (13.1)	0.431	5.8 (15.2)
Financial difficulties	87	6.1 (14.9)	89	12.7 (26.8)	0.045	18.6 (28.6)
EORTC QLQ-BR23 functional scales						
Body image	88	79.4 (29.5)	90	88.7 (22.6)	0.019	81.9 (22.6)
Sexual functioning	79	12.0 (20.3)	86	11.6 (20.3)	0.900	19.2 (23.2)
Sexual enjoyment ^b	30	33.3 (32.8)	26	41.0 (36.9)	0.412	55.1 (25.6)
Future perspective	86	41.1 (32.6)	87	43.3 (36.0)	0.673	47.6 (34.1)
EORTC QLQ-BR23 symptom scales						
Systemic therapy side effects	87	18.0 (16.0)	89	15.9 (12.7)	0.339	15.8 (14.3)
Breast symptoms	88	20.4 (23.4)	90	15.2 (19.3)	0.110	17.6 (16.7)
Arm symptoms	88	21.5 (28.5)	90	15.5 (20.7)	0.115	21.0 (21.1)
Upset by hair loss ^c	22	15.2 (24.6)	24	9.7 (15.5)	0.382	5.3 (19.3)

^aReference baseline value for recurrent and metastatic breast cancer patients across all lines of treatment.¹²

^bThe patients were asked to answer this question only if they responded that they were sexually active in a previous question.

^cOnly patients with alopecia were asked to answer this question.

EORTC QLQ-BR-23, European organisation for research and treatment of cancer breast-specific questionnaire; EORTC QLQ-C30, European organisation for research and treatment of cancer core questionnaire; QoL, quality of life; SD, standard deviation.




Figure 1. GHS/QoL mean scores in the EORTC QLQ-C30 scales by visit. BL, baseline; C, cycle; CI, confidence interval; D, day; EORTC QLQ-C30, European organisation for research and treatment of cancer core questionnaire; FUL, fulvestrant; GHS/QoL, global health status/quality of life; PAL, palbociclib; PBO, placebo; POST-T, post-treatment visit.

therapy side effects when the analysis of mean CFB by visit was performed (Supplemental Table S4). No significant differences were observed for other functional, symptom or GHS/QoL scales.

Placebo/fulvestrant. The GHS/QoL mean scores were numerically improved up to post-treatment visit (Figure 1). Statistically significant increases in the mean CFB during all study treatment visits were found for GHS/QoL (Table S3).

Significant improvements were found at different time points in the mean CFB by visit for role functioning, emotional functioning and appetite loss (Table S3). Significant impairment was found for cognitive functioning, future perspective and systemic therapy side effects (Supplemental Table S4). Most scales worsened in both study arms at the post-treatment visit since the reason for terminating the treatment was PD in 82.4% of the cases (Supplemental Table S5).

Clinically meaningful improvements

Clinically meaningful improvements (based on MID values) were observed in both treatment arms at different time points for emotional functioning, pain, appetite loss and breast symptoms; while such improvements developed for arm symptoms in the palbociclib/fulvestrant arm, in the placebo/fulvestrant arm improvements developed for role functioning and dyspnoea (Figure 2).

Comparison of CFB between treatment arms

The overall CFB for all scales of the QLQ-C30 and QLQ-BR23 questionnaires are presented in Figure 3. Significant improvements were observed for GHS/QoL [6.8 (95% CI: 3.5–10.0) versus 0.2 (95% CI: –3.2–3.6); $p=0.005$], and appetite loss [–7.3 (95% CI: –10.4–4.3) versus –0.6 (95% CI: –5.7–4.5); $p=0.021$], and significantly less deterioration for constipation [2.5 (95% CI: –2.0–6.9) versus 10.5 (95% CI: 5.0–15.9); $p=0.027$] and for systematic therapy side effects [2.7 (95% CI: 0.2–5.1) versus 8.3 (95% CI: 5.2–11.4); $p=0.004$] favouring the control arm with placebo/fulvestrant.

According to the linear mixed model analysis, the change of GHS/QoL score from baseline to cycle 7 was 1.5 (95% CI: –2.5–5.5) for palbociclib/fulvestrant versus 7.9 (95% CI: 3.4–12.4) for placebo/fulvestrant. The mean difference was –6.4 (95% CI: –12.4–0.5; $p=0.035$), maintained up to cycle 19, showing a higher improvement in the placebo/fulvestrant arm. No significant differences were observed between treatment arms at other time points (Supplemental Figure S2).

Time to deterioration

The median TTD in GHS/QoL, using a MID = 10, was 11.1 months with palbociclib/fulvestrant versus 30.3 months with placebo/fulvestrant (aHR: 1.57, 95% CI: 1.03–2.39; $p=0.036$) ((Figure 4(a)). The analysis performed only in patients without a PFS event showed similar results, 11.1 months with palbociclib/fulvestrant versus 30.3 months with placebo/fulvestrant (aHR 2.04; 95% CI: 1.11–3.77; $p=0.023$). No statistically significant difference was seen in TTD in the analysis performed in patients with a PFS event (aHR: 1.15, 95% CI: 0.61–2.18; $p=0.658$) (Figures 4(b) and (c)).

No significant differences were seen in that respect among patients with or without a PFS event in both arms, palbociclib/fulvestrant (aHR: 1.21; 95% CI: 0.69–2.11, $p=0.504$) and placebo/fulvestrant (aHR: 0.55; 95% CI: 0.26–1.13, $p=0.104$) (Supplemental Figure S3).

No significant differences were seen for the risk of deterioration between the study arms of the median TTD for the other QLQ-C30 and QLQ-BR23 scales, except for arm symptoms, using a MID = 5, with a median TTD of




Figure 2. Clinically meaningful improvements from baseline in the EORTC QLQ-C30 and QLQ-BR23 scales by treatment arm.

Baseline is defined as the last observed measurement on or before the date of first dose of study drug. The time profile provides the average estimates for the CFB for the interval from baseline to the respective cycle as derived from the linear mixed model. An increase from baseline indicates an improvement in functional items (a – emotional functioning and f – role functioning). A decrease from baseline indicates an improvement in symptom scales (b – pain, c – appetite loss, d – breast symptoms, e – arms symptoms and g – dyspnoea). MID values indicated by red lines (Cocks *et al.*¹² and Osoba *et al.*¹³) have been used for the consideration of CMI.

C, cycle; CFB, change from baseline; CI, confidence interval; CMI, clinically meaningful improvements; D, day; EORTC QLQ-BR-23, European organisation for research and treatment of cancer breast-specific questionnaire; EORTC QLQ-C30, European organisation for research and treatment of cancer core questionnaire; MID, minimally important difference; PAL, palbociclib; PBO, placebo; POST-T, post-treatment visit.




Figure 3. Overall CFB in EORTC QLQ-C30 and BR23 scales. CFB were determined using a repeated-measures mixed-effect model. (a) Analysis of CFB for GHS/QoL and functional scales and (b) analysis of CFB for symptom scales.

*Statistically significant difference in CFB scores between treatment arms.

EORTC QLQ-BR-23, European organisation for research and treatment of cancer breast-specific questionnaire; EORTC QLQ-C30, European organisation for research and treatment of cancer core questionnaire; CFB, change from baseline; FUL, fulvestrant; GHS/QoL, global health status/quality of life; PAL, palbociclib; PBO, placebo.

20.4 months with palbociclib/fulvestrant *versus* 8.3 months with placebo/fulvestrant (aHR: 0.59, 95% CI: 0.39–0.88; $p = 0.011$). In the Forest-plot with the QLQ-C30 and QLQ-BR23 scales for TTD, a trend towards one of the treatment arms cannot be observed, the distribution from the unit towards both sides is heterogenous (Figure 5).

Subgroup analyses of TTD in GHS/QoL showed longer delayed deterioration with placebo/fulvestrant over palbociclib/fulvestrant (Supplemental Figure S4).

Discussion

Maintaining QoL is a key goal of the treatment of ABC patients. Although treatments can reduce symptoms, thereby slowing the impairment in QoL and prolonging time to PD, treatment-related toxicities affect the HRQoL. Here, we present detailed cancer-related and breast-cancer-specific PROs regarding the palbociclib/

fulvestrant administration in the first-line treatment of endocrine-sensitive HR+/HER2– ABC patients. We demonstrated that the favourable efficacy achieved with palbociclib/fulvestrant is accompanied by maintained overall QoL throughout the study treatment period. Interestingly, baseline GHS/QoL and functioning subscale scores were maintained and similar between study arms, except for GHS/QoL, appetite loss, constipation and systemic therapy side effects, which statistically favoured the control over time. Appetite loss, constipation, and systemic therapy side effects, as treatment-related toxicities that can adversely affect the HRQoL, could have contributed to the reduction in GHS/QoL observed in our study. Indeed, this is a relative reduction compared to the placebo arm and not an absolute reduction, since the GHS/QoL scores in the experimental arm are maintained and numerically improved during treatment compared to baseline values. In addition, declines in these symptom scales were




Figure 4. Kaplan–Meier estimates for TTD in GHS/QoL based on the EORTC QLQ-C30 questionnaire data. Baseline is defined as the last observed measurement on or before the date of first dose of study drug. The aHR was obtained using a stratified Cox proportional hazards model with treatment arm and the stratification factors [disease site (visceral *versus* non-visceral) and (recurrent *versus* de novo) metastatic disease] as covariates. (a) Analysis of all QoL population by treatment arm, (b) analysis of patients without progression event and (c) analysis of patients with progression event. CI, confidence interval; EORTC QLQ-C30, European organisation for research and treatment of cancer core questionnaire; FUL, fulvestrant; GHS/QoL, global health status/quality of life; PAL, palbociclib; PBO, placebo; TTD, time to deterioration.

consistent with the safety profile observed with palbociclib/fulvestrant in the FLIPPER trial.¹ In the ITT population, most adverse events (AEs) observed in the experimental arm were of mild severity (except for neutropenia), with higher rates of Common Terminology Criteria for Adverse Events grade I–II anorexia reported in the palbociclib/fulvestrant group (16%) *versus* the placebo/fulvestrant arm (9.5%) and no differences in grade I–II constipation (19%). Permanent discontinuation of the whole study treatment due to AEs was similar in both arms and occurred in four patients (4.3%) receiving palbociclib/fulvestrant and 4 patients (4.2%) receiving placebo/fulvestrant. Overall, these results may reflect the importance of chronic low-grade toxicities in patient experience, and how in regulatory clinical trials, these are generally not captured well.¹⁵

Although no statistical or clinically meaningful differences were observed in the key subdomains of the EORTC QLQ-C30 and QLQ-B23 questionnaires, patients treated with placebo/fulvestrant experienced a significantly greater delay in deterioration of GHS/QoL than patients treated with palbociclib/fulvestrant. In addition, patients treated with ET in monotherapy without PD experienced delayed TTD in GHS/QoL but not patients whose disease progressed, suggesting that negative impacts on functioning scores may be primarily due to the study treatment AEs.

These PROs from the FLIPPER trial add to the growing body of evidence reported of CDK4/6 inhibitors trials.¹⁶ For postmenopausal patients, the majority of trials report that HRQoL has been maintained in the first-line setting^{17–20} or improved in the second-line or later-line setting.²¹ Our




Figure 5. Forest plot TTD in the various scales of the EORTC QLQ-C30 and EORTC QLQ_BR23 questionnaires. The aHRs were obtained using a stratified Cox proportional hazards model with treatment arm, the stratification factors [disease site [visceral *versus* non-visceral] and [recurrent *versus* de novo] metastatic disease] as covariates. aHR, adjusted hazard ratio; CI, confidence interval; EORTC QLQ-BR-23, European organisation for research and treatment of cancer breast-specific questionnaire; EORTC QLQ-C30, European organisation for research and treatment of cancer core questionnaire; FUL, fulvestrant; GHS/QoL, global health status/quality of life; MID, minimally important difference; PAL, palbociclib; PBO, placebo.

results are not fully consistent with those observed in the PALOMA-3 trial, where premenopausal and postmenopausal patients with endocrine-resistant HR+/HER2- metastatic breast cancer were randomised to palbociclib/fulvestrant *versus* placebo/fulvestrant. This trial demonstrated improved PFS and a non-statistically significant increase in OS²² with a delay in the TTD of QoL and pain symptoms.²³ This inconsistency regarding QoL may reflect a younger, more heavily pre-treated, population with fewer comorbidities included into the PALOMA-3 trial. Conversely, the FLIPPER trial recruited only postmenopausal patients with ABC, older (median age was 64 in the FLIPPER *versus* 57 in the PALOMA-3 trial), sensitive to ET, less symptomatic and who were receiving the first-line therapy. Sensitivity was defined as *de novo* ABC or recurrent disease ≥ 1 year after the completion of ≥ 5 years of (neo) adjuvant ET, a patient population specifically excluded in the PALOMA-3 trial. Similar results were observed with palbociclib over placebo in PALOMA-2 trial, where the addition of palbociclib to letrozole significantly improved PFS while

maintaining HRQoL in treatment-naïve postmenopausal women with ER+/HER2- MBC.²⁴ However, in PALOMA-2 study, HRQoL deterioration was delayed in patients with response and/or no progression. This inconsistency regarding HRQoL may be due to type of ET and less sensitivity to ET (22% of patients with a relapse ≤ 12 months) into the PALOMA-2 trial.² Finally, when palbociclib in combination with ET has been compared *versus* chemotherapy (capecitabine) in a more heavily pre-treated, endocrine resistance population HRQoL was maintained regardless of menopausal setting,^{21,25} albeit in PEARL trial patients showed earlier HRQoL deterioration with chemotherapy.²¹

Our results shed light on benefit-risk assessments to inform decision-making for palbociclib in postmenopausal patients with ABC. Maintaining HRQoL in patients with ABC is crucial, especially for drugs that improve PFS with no OS benefit. Efficacy data recently published¹ shown OS data were still immature at the time of this analysis with only a 15% of ITT population with

an OS event. Ongoing follow-up will help for a better knowledge of the risk–benefit profile of palbociclib (expected date of publication 2025).

Potential limitations of FLIPPER study are as follows: (i) a small number of participants in a phase II study (ii) and the number of cycles included in the analysis. The cut-off of this analysis, not pre-planned, was cycle 22 because at this point 50% of patients had received the study treatment and the overall questionnaires compliance was high in both treatment arms. Therefore, delayed TTD were not captured and $\geq 50\%$ of patients were still on treatment at the analysis cut-off date. Further follow-up and updated data collection will help to mitigate this bias. Another potential limitation in the design of PRO analyses should be considered as data cannot be assumed missing at random because frail patients are likely to have lower compliance and bias could occur as a result. To address this limitation, the mixed-model approach was chosen as well as the high compliance rates of treated patients in all study visits minimised the impact of this limitation. Despite these, strength of FLIPPER study are (i) a randomised double-blinded design, (ii) high compliance rates $\geq 90\%$ and (iii) the study included multiple instruments with a dedicated questionnaire to identify breast-cancer-specific functions and symptoms and differentiated MID values for each multi-item scale of EORTC QLQ-C30 and EORTC QLQ-BR23 modules.

Conclusions

Our findings provide evidence that overall HRQoL in the FLIPPER trial was maintained in postmenopausal women with endocrine-sensitive HR+/HER2– ABC receiving palbociclib in combination with fulvestrant as first-line treatment. Taken together, the improved clinical efficacy, manageable safety profile and PRO results provide a meaningful assessment of the benefits, risks and tolerability of palbociclib/fulvestrant in this patient population.

Declarations

Ethics approval and consent to participate

The study protocol was approved by every site's institutional review board (IRB) and every national regulatory agency. The IRBs that approved the study were Clínica Parc de Salut Mar, Barcelona, Spain; Clinical Research Ethics

Committee of the Cork Teaching Hospitals, Cork, Ireland (no approval numbers available). All patients gave informed consent in writing. Data were analysed by a statistician employed by GEICAM.

Consent for publication

Not applicable.

Author contribution(s)

Ariadna Tibau: Investigation; Resources; Supervision; Writing – original draft; Writing – review & editing.

M. Teresa Martínez: Data curation; Investigation; Resources; Visualisation; Writing – review & editing.

Manuel Ramos: Data curation; Investigation; Resources; Visualisation; Writing – review & editing.

Luis de la Cruz-Merino: Data curation; Investigation; Resources; Visualisation; Writing – review & editing.

Ana Santaballa: Data curation; Investigation; Resources; Visualisation; Writing – review & editing.

Miriam O'Connor: Data curation; Investigation; Resources; Visualisation; Writing – review & editing.

Noelia Martínez-Jañez: Data curation; Investigation; Resources; Visualisation; Writing – review & editing.

Fernando Moreno: Data curation; Investigation; Resources; Visualisation; Writing – review & editing.

Isaura Fernández: Data curation; Investigation; Resources; Visualisation; Writing – review & editing.

Juan Antonio Virizuela: Data curation; Investigation; Resources; Visualisation; Writing – review & editing.

Jesús Alarcón: Data curation; Investigation; Resources; Visualisation; Writing – review & editing.

Juan de La Haba-Rodríguez: Data curation; Investigation; Resources; Visualisation; Writing – review & editing.

Pedro Sánchez-Rovira: Data curation; Investigation; Resources; Visualisation; Writing – review & editing.

Cinta Rosa Albacar: Data curation; Investigation; Resources; Visualisation; Writing – review & editing.

Coralia Bueno Muiño: Data curation; Investigation; Resources; Visualisation; Writing – review & editing.

Catherine Kelly: Data curation; Methodology; Resources; Visualisation; Writing – review & editing.

Maribel Casas: Formal analysis; Visualisation; Writing – original draft; Writing – review & editing.

Susana Bezares: Methodology; Project administration; Supervision; Visualisation; Writing – original draft; Writing – review & editing.

Libertad Rosell: Project administration; Visualisation; Writing – review & editing.

Joan Albanell: Conceptualisation; Data curation; Funding acquisition; Investigation; Methodology; Project administration; Resources; Supervision; Visualisation; Writing – original draft; Writing – review & editing.

Acknowledgements

We acknowledge the patients who participated in the FLIPPER study and their families and all the participating investigators. We also acknowledge the support of the staff at each study site and at both GEICAM and Cancer Trials Ireland headquarters. We would like to thank Elsevier Language Editing Services for English language editing.

Funding

The authors disclosed receipt of the following financial support for the research, authorship and/or publication of this article: The trial sponsor is GEICAM Spanish Breast Cancer Group. Two funding companies provided the following: AstraZeneca provided fulvestrant and study grant, and Pfizer Inc. provided palbociclib and placebo.

Competing interests

Dr. Tibau has received speaker fees from Novartis and Eisai. Dr. Ramos has received speaker's bureau from Novartis, Pfizer and Roche Farma. Dr. de La Cruz-Merino has received advisory board fees from MSD-Merk, Roche Farma, Bristol-Myers-Squibb, Pierre-Fabré, Amgen and Novartis; research

funding from MSD-Merck, Roche Farma, Celgene; speaking fees from MSD-Merck, Roche Farma, Bristol-Myers-Squibb and Amgen; grant support from Bristol-Myers-Squibb and Roche Farma. Dr. Santaballa has received consulting or advisory role fees from GSK, Clovis, MSD, AstraZeneca, Roche and Pfizer; speakers' honoraria from GSK, Clovis, Roche, MSD, AstraZeneca and Pfizer; and grant support by Pfizer, GSK and MSD. Dr. Martínez-Jañez has received advisory board fees from Roche Farma, Astra Zeneca, Pfizer, Novartis, Lilly, Daiichi Sankyo, Agendia and Eisai. Dr. Moreno has received advisory board fees from Roche/Genentech, Novartis, Pfizer, AstraZeneca, MSD-Merck and Daiichi Sankyo/AstraZeneca; speaker's bureau fees from Pfizer; travel accommodations expenses from Roche/Genentech, Pfizer, Novartis, Daiichi Sankyo/Astra Zeneca. Dr. Fernández has received consultant or advisory fees from MSD-Astra Zeneca; speaker's bureau fees from Pfizer, AstraZeneca, Roche, MSD, Clovis and GSK. Dr. Alarcón: has received honoraria from GSK, Clovis, Roche and AstraZeneca; consulting or advisory board honoraria from GSK and Clovis; speaker and expert testimony fees from GSK, Clovis and Roche; and travel and accommodation support from GSK. Dr. de La Haba-Rodríguez has received speaker's honoraria from AstraZeneca, Pfizer, Novartis and Lilly. Dr. Sánchez-Rovira has received honoraria from Novartis, Lilly, Pfizer, Roche and Seagen. Dr. Bueno Muiño has received speaker fees from Novartis, Lilly, AstraZeneca, BMS, Pfizer and GSK. Dr. Albanell has received consulting or advisory role fees from Roche, Pfizer, Amgen, MSD, Lilly and Daiichi-Sankyo; research funding or grant support trials by Roche, Pfizer, Amgen, MSD, Lilly, Daiichi-Sankyo; and travel and accommodation support from Roche, Pfizer, Amgen, MSD, Lilly and Daiichi-Sankyo. All remaining authors have declared no conflicts of interest.

GEICAM has received research funding from Roche/Genentech, Bristol-Myers Squibb, Novartis, Pfizer, Celgene, AstraZeneca, Merck Sharp & Dohme, Pierre Fabre and Takeda.

A complete list of the FLIPPER trial collaborators is provided in the Supplemental Appendix.

Availability of data and materials

The datasets used and/or analysed during this study are available from the corresponding author on reasonable request.

ORCID iD

Ariadna Tibau  <https://orcid.org/0000-0003-0229-6987>

Supplemental material

Supplemental material for this article is available online.

References

- Albanell J, Martínez MT, Ramos M, *et al.* Randomized phase II study of fulvestrant plus palbociclib or placebo in endocrine-sensitive, hormone receptor-positive/HER2-advanced breast cancer: GEICAM/2014-12 (FLIPPER). *Eur J Cancer* 2022; 161: 26–37.
- Finn RS, Martin M, Rugo HS, *et al.* Palbociclib and letrozole in advanced breast cancer. *N Engl J Med* 2016; 375: 1925–1936.
- Im SA, Lu YS, Bardia A, *et al.* Overall survival with ribociclib plus endocrine therapy in breast cancer. *N Engl J Med* 2019; 381: 307–316.
- Goetz MP, Toi M, Campone M, *et al.* MONARCH 3: abemaciclib as initial therapy for advanced breast cancer. *J Clin Oncol* 2017; 35: 3638–3646.
- Cherny NI, Dafni U, Bogaerts J, *et al.* ESMO-magnitude of clinical benefit scale version 1.1. *Ann Oncol* 2017; 28: 2340–2366.
- Schnipper LE, Davidson NE, Wollins DS, *et al.* Updating the American society of clinical oncology value framework: revisions and reflections in response to comments received. *J Clin Oncol* 2016; 34: 2925–2934.
- Cardoso F, Paluch-Shimon S, Senkus E, *et al.* 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). *Ann Oncol* 2020; 31: 1623–1649.
- Eisenhauer EA, Therasse P, Bogaerts J, *et al.* New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). *Eur J Cancer* 2009; 45: 228–247.
- Aaronson NK, Ahmedzai S, Bergman B, *et al.* The European organization for research and treatment of cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. *J Natl Cancer Inst* 1993; 85: 365–376.
- Sprangers MA, Groenvold M, Arraras JI, *et al.* The European organization for research and treatment of cancer breast cancer-specific quality-of-life questionnaire module: first results from a three-country field study. *J Clin Oncol* 1996; 14: 2756–2768.
- Fayers PM. Interpreting quality of life data: population-based reference data for the EORTC QLQ-C30. *Eur J Cancer* 2001; 37: 1331–1334.
- Cocks K, King MT, Velikova G, *et al.* Evidence-based guidelines for interpreting change scores for the European organisation for the research and treatment of cancer quality of life questionnaire core 30. *Eur J Cancer* 2012; 48: 1713–1721.
- Osoba D, Rodrigues G, Myles J, *et al.* Interpreting the significance of changes in health-related quality-of-life scores. *J Clin Oncol* 1998; 16: 139–144.
- Scott NW, Fayers PM, Aaronson NK, Bottomley A, de Graeff A, Groenvold M, Gundy C, Koller M, Petersen MA and Mirjam AG Sprangers on behalf of the EORTC Quality of Life Group. EORTC QLQ-C30 reference values 2008. https://www.eortc.org/app/uploads/sites/2/2018/02/reference_values_manual2008.pdf (2008, accessed 10 January 2023).
- Hadji P, Jackisch C, Bolten W, *et al.* COMPLIANCE and arthralgia in clinical therapy: the COMPACT trial, assessing the incidence of arthralgia, and compliance within the first year of adjuvant anastrozole therapy. *Ann Oncol* 2014; 25: 372–377.
- Ribnikar D, Volovat SR and Cardoso F. Targeting CDK4/6 pathways and beyond in breast cancer. *Breast* 2019; 43: 8–17.
- Goetz MP, Martin M, Tokunaga E, *et al.* Health-related quality of life in MONARCH 3: abemaciclib plus an aromatase inhibitor as initial therapy in HR+, HER2- advanced breast cancer. *Oncologist* 2020; 25: e1346–e1354.
- Verma S, O’Shaughnessy J, Burris HA, *et al.* Health-related quality of life of postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer treated with ribociclib + letrozole: results from MONALEESA-2. *Breast Cancer Res Treat* 2018; 170: 535–545.
- Fasching PA, Beck JT, Chan A, *et al.* Ribociclib plus fulvestrant for advanced breast cancer: Health-related quality-of-life analyses from the MONALEESA-3 study. *Breast* 2020; 54: 148–54.
- Cardoso F, Senkus E, Costa A, *et al.* 4th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 4) dagger. *Ann Oncol* 2018; 29: 1634–1657.
- Kahan Z, Gil-Gil M, Ruiz-Borrego M, *et al.* Health-related quality of life with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor-positive metastatic breast cancer:

- patient-reported outcomes in the PEARL study. *Eur J Cancer* 2021; 156: 70–82.
22. Turner NC, Slamon DJ, Ro J, *et al.* Overall survival with palbociclib and fulvestrant in advanced breast cancer. *N Engl J Med* 2018; 379: 1926–1936.
23. Harbeck N, Iyer S, Turner N, *et al.* Quality of life with palbociclib plus fulvestrant in previously treated hormone receptor-positive, HER2-negative metastatic breast cancer: patient-reported outcomes from the PALOMA-3 trial. *Ann Oncol* 2016; 27: 1047–1054.
24. Rugo HS, Dieras V, Gelmon KA, *et al.* Impact of palbociclib plus letrozole on patient-reported health-related quality of life: results from the PALOMA-2 trial. *Ann Oncol* 2018; 29: 888–894.
25. Lee S, Im SA, Kim GM, *et al.* Patient-reported outcomes of palbociclib plus exemestane with GnRH agonist versus capecitabine in premenopausal women with hormone receptor-positive metastatic breast cancer: a prospective, open-label, randomized phase II trial (KCSG-BR 15-10). *Cancers (Basel)* 2020; 12: 3265.

Visit SAGE journals online
[journals.sagepub.com/
home/tam](https://journals.sagepub.com/home/tam)

 SAGE journals